专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07982024B2 Antibodies to insulin-like growth factor I receptor 有权
标题翻译：胰岛素样生长因子I受体的抗体
公开(公告)号：US07982024B2
公开(公告)日：2011-07-19
申请号：US12756417
申请日：2010-04-08
申请人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose Ramon Corvalan , Michael Gallo
发明人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose Ramon Corvalan , Michael Gallo
IPC分类号： C07H21/04 , C12N15/00 , C12N5/07 , C12N5/16 , A61K39/395 , C07K16/00
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
摘要翻译：本发明涉及特异性结合胰岛素样生长因子I受体（IGF-1R）的抗体及其抗原结合部分，其优选为人IGF-1R。本发明还涉及人抗IGF-1R抗体，包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。本发明还涉及衍生自抗IGF-1R抗体和编码这种分子的核酸分子的分离的重链和轻链免疫球蛋白分子。本发明还涉及制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用抗体及其组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗IGF-1R抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的基因治疗方法和转基因动物。

2. 发明申请

US20050245456A1 Combination therapy to prevent and treat diarrhea induced by cancer treatment 审中-公开
标题翻译：联合治疗预防和治疗由癌症治疗引起的腹泻
公开(公告)号：US20050245456A1
公开(公告)日：2005-11-03
申请号：US11119211
申请日：2005-04-28
申请人： Diane Healey , Jean Beebe , James O'Leary , W. Roberts , Anthony Tolcher , Mark Huberman
发明人： Diane Healey , Jean Beebe , James O'Leary , W. Roberts , Anthony Tolcher , Mark Huberman
IPC分类号： A61K31/138 , A61K31/425 , A61K31/56 , A61K38/08
CPC分类号： A61K45/06 , A61K31/138 , A61K31/425 , A61K31/56 , A61K2300/00
摘要： This invention relates to a method of treating drug side effects in cancer treatment. More particularly, the present invention relates to preventing, reducing, alleviating, or reversing diarrhea caused by the administration of the isothiazole 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide in the treatment of cancer comprising the step of administering to a patient in need of such treatment, prior to, simultaneously, or sequentially, a therapeutically effective amount of 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an anti-diarrheal agent, a bulking agent, or an anti-estrogen. The combinations of the present invention may optionally include an anti-hypertensive agent.
摘要翻译：本发明涉及一种治疗癌症治疗药物副作用的方法。更具体地说，本发明涉及通过给予异噻唑3-（4-溴-2,6-二氟 - 苄氧基）-5- [3-（4-吡咯烷-1-基）苯基）苯甲酸酯而引起的腹泻的预防，减轻，减轻或逆转，丁基） - 脲基] - 异噻唑-4-羧酸酰胺在治疗癌症中的用途包括以下步骤：在需要这种治疗的患者之前，同时或依次给予治疗有效量的3 - （4-溴-2,6-二氟 - 苄氧基）-5- [3-（4-吡咯烷-1-基 - 丁基） - 脲基] - 异噻唑-4-羧酸酰胺或其药学上可接受的盐，和治疗有效量的抗腹泻剂，填充剂或抗雌激素。本发明的组合可以任选地包括抗高血压剂。

3. 发明授权

US08642037B2 Antibodies to insulin-like growth factor I receptor 有权
标题翻译：胰岛素样生长因子I受体的抗体
公开(公告)号：US08642037B2
公开(公告)日：2014-02-04
申请号：US13169474
申请日：2011-06-27
申请人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose Ramon Corvalan , Michael Gallo
发明人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose Ramon Corvalan , Michael Gallo
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
摘要翻译：本发明涉及特异性结合胰岛素样生长因子I受体（IGF-1R）的抗体及其抗原结合部分，其优选为人IGF-1R。本发明还涉及人抗IGF-1R抗体，包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。本发明还涉及衍生自抗IGF-1R抗体和编码这种分子的核酸分子的分离的重链和轻链免疫球蛋白分子。本发明还涉及制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用抗体及其组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗IGF-1R抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的基因治疗方法和转基因动物。

4. 发明申请

US20120005767A1 ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR 有权
标题翻译：抗胰岛素样生长因子I受体
公开(公告)号：US20120005767A1
公开(公告)日：2012-01-05
申请号：US13169474
申请日：2011-06-27
申请人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose R. Corvalan , Michael Gallo
发明人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose R. Corvalan , Michael Gallo
IPC分类号： A01K67/027 , A61K39/395 , C07H21/00 , A61P35/00 , A61K49/00 , G01N33/566 , C12P21/08 , C12P21/00 , C12N5/10 , C12N1/21 , C12N1/15 , C12N5/16 , C07K16/28 , C12N15/63
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
摘要翻译：本发明涉及特异性结合胰岛素样生长因子I受体（IGF-1R）的抗体及其抗原结合部分，其优选为人IGF-1R。本发明还涉及人抗IGF-1R抗体，包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。本发明还涉及衍生自抗IGF-1R抗体和编码这种分子的核酸分子的分离的重链和轻链免疫球蛋白分子。本发明还涉及制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用抗体及其组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗IGF-1R抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的基因治疗方法和转基因动物。

5. 发明授权

US07815907B2 Antibodies to insulin-like growth factor I receptor 有权
标题翻译：胰岛素样生长因子I受体的抗体
公开(公告)号：US07815907B2
公开(公告)日：2010-10-19
申请号：US11144248
申请日：2005-06-02
申请人： Bruce D Cohen , Jean Beebe , Penelope E Miller , James D Moyer , Jose R Corvalan , Michael Gallo
发明人： Bruce D Cohen , Jean Beebe , Penelope E Miller , James D Moyer , Jose R Corvalan , Michael Gallo
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
摘要翻译：本发明涉及特异性结合胰岛素样生长因子I受体（IGF-1R）的抗体及其抗原结合部分，其优选为人IGF-1R。本发明还涉及人抗IGF-1R抗体，包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。本发明还涉及衍生自抗IGF-1R抗体和编码这种分子的核酸分子的分离的重链和轻链免疫球蛋白分子。本发明还涉及制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用抗体及其组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗IGF-1R抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的基因治疗方法和转基因动物。

6. 发明申请

US20100255538A1 ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR 有权
标题翻译：抗胰岛素样生长因子I受体
公开(公告)号：US20100255538A1
公开(公告)日：2010-10-07
申请号：US12756417
申请日：2010-04-08
申请人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose R. Corvalan , Michael Gallo
发明人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose R. Corvalan , Michael Gallo
IPC分类号： C12P21/08 , C07H21/04 , C12N15/63 , C12N5/07
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
摘要翻译：本发明涉及特异性结合胰岛素样生长因子I受体（IGF-1R）的抗体及其抗原结合部分，其优选为人IGF-1R。本发明还涉及人抗IGF-1R抗体，包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。本发明还涉及衍生自抗IGF-1R抗体和编码这种分子的核酸分子的分离的重链和轻链免疫球蛋白分子。本发明还涉及制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用抗体及其组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗IGF-1R抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的基因治疗方法和转基因动物。

7. 发明授权

US07700742B2 Antibodies to insulin-like growth factor I receptor 有权
公开(公告)号：US07700742B2
公开(公告)日：2010-04-20
申请号：US11144222
申请日：2005-06-02
申请人： Bruce D Cohen , Jean Beebe , Penelope E Miller , James D Moyer , Jose R Corvalan , Michael Gallo
发明人： Bruce D Cohen , Jean Beebe , Penelope E Miller , James D Moyer , Jose R Corvalan , Michael Gallo
IPC分类号： C12P21/08
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

8. 发明申请

US20070197517A1 Combination therapy for hyperproliferative disease 审中-公开
标题翻译：过度增生性疾病的联合治疗
公开(公告)号：US20070197517A1
公开(公告)日：2007-08-23
申请号：US10643546
申请日：2003-08-19
申请人： Jitesh Jani , Jean Beebe , Tracey Schaeffer , Diane Healey , Karen Ferrante , James O'Leary
发明人： Jitesh Jani , Jean Beebe , Tracey Schaeffer , Diane Healey , Karen Ferrante , James O'Leary
IPC分类号： A61K31/41 , A61K31/35 , A61K31/53 , C07D239/42
CPC分类号： A61K31/282 , A61K31/337 , A61K31/425 , A61K31/427 , A61K31/454 , A61K31/473 , A61K31/4745 , A61K31/496 , A61K31/513 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K2300/00
摘要： This invention relates a method of treating hyperproliferative diseases. More particularly, the present invention relates to a method of treating hyperproliferative diseases, such as cancer, comprising the step of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a therapeutically effective amount of a taxane derivative, a platinium coordination complex selected from the group consisting of carboplatin, tetraplatin, and topotecan, a nucleoside analog selected from the group consisting of gemcitabine hydrochloride and 5-FU, an anthracycline, a topoisomerase selected from the group consisting of etoposide, teniposide, amsacrine, topotecan, and Camptosar®, an aromatase inhibitor; and (ii) a therapeutically effective amount of an isothiazole derivative. The combinations of the present invention may optionally include an anti-hypertensive agent. This invention also relates to pharmaceutical compositions useful in the treatment of hyperproliferative diseases in mammals, containing such combinations. The present invention also relates to kits having a first compartment with a compound of formula 1 and a second compartment containing a taxane derivative, a platinum coordination complex, a nucleoside analog, an anthracycline, a topoisomerase inhibitor, or an aromatase inhibitor and a third compartment containing an anti-hypertensive agent.
摘要翻译：本发明涉及一种治疗过度增殖性疾病的方法。更具体地说，本发明涉及治疗过度增殖性疾病如癌症的方法，其包括以下步骤：同时或依次给予需要这种治疗的哺乳动物，（i）治疗有效量的紫杉烷衍生物，选自卡铂，四铂和托泊替康的铂配位络合物，选自盐酸吉西他滨和5-FU的核苷类似物，蒽环类，拓扑异构酶，其选自依托泊苷，替尼泊苷，安吖啶，拓扑替康和Camptosar（芳香酶抑制剂）; 和（ii）治疗有效量的异噻唑衍生物。本发明的组合可以任选地包括抗高血压剂。本发明还涉及可用于治疗哺乳动物中含有这种组合的过度增殖性疾病的药物组合物。本发明还涉及具有具有式1化合物的第一隔室和含有紫杉烷衍生物，铂配位络合物，核苷类似物，蒽环类，拓扑异构酶抑制剂或芳香酶抑制剂和第三隔室的第二隔室的试剂盒含有抗高血压药。

9. 发明授权

US07037498B2 Antibodies to insulin-like growth factor I receptor 有权
标题翻译：胰岛素样生长因子I受体的抗体
公开(公告)号：US07037498B2
公开(公告)日：2006-05-02
申请号：US10038591
申请日：2002-01-04
申请人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose R. Corvalan , Michael Gallo
发明人： Bruce D. Cohen , Jean Beebe , Penelope E. Miller , James D. Moyer , Jose R. Corvalan , Michael Gallo
IPC分类号： A61K39/395
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
摘要翻译：本发明涉及特异性结合胰岛素样生长因子I受体（IGF-1R）的抗体及其抗原结合部分，其优选为人IGF-1R。本发明还涉及人抗IGF-1R抗体，包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。本发明还涉及衍生自抗IGF-1R抗体和编码这种分子的核酸分子的分离的重链和轻链免疫球蛋白分子。本发明还涉及制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用抗体及其组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗IGF-1R抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的基因治疗方法和转基因动物。

10. 发明申请

US20050281812A1 Antibodies to insulin-like growth factor I receptor 有权
公开(公告)号：US20050281812A1
公开(公告)日：2005-12-22
申请号：US11144222
申请日：2005-06-02
申请人： Bruce Cohen , Jean Beebe , Penelope Miller , James Moyer , Jose Corvalan , Michael Gallo
发明人： Bruce Cohen , Jean Beebe , Penelope Miller , James Moyer , Jose Corvalan , Michael Gallo
IPC分类号： A01K67/027 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , C07K14/72 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式